EU regulator authorises AstraZeneca vaccine for all adults

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Regulators have authorised AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union&period;<&sol;p>&NewLine;<p>The European Medicines Agency &lpar;EMA&rpar; licensed the vaccine to be used in people 18 and over&comma; though concerns had been raised this week that not enough data exist to prove it works in older people&period;<&sol;p>&NewLine;<p>The shot is the third Covid-19 vaccine given the green light by the European Medicines Agency&comma; after ones made by Pfizer and Moderna&period; Both were authorised for all adults&period;<&sol;p>&NewLine;<p>The EMA’s decision requires final approval from the European Commission&comma; a process that occurred swiftly with the other vaccines&period;<&sol;p>&NewLine;<p>With trials showing about 60&percnt; efficacy&comma; the vaccine appears to offer less protection than ones already authorised&comma; but experts have said any vaccine with an efficacy rate of over 50&percnt; could help stop outbreaks&period;<&sol;p>&NewLine;<p>The agency recommended the vaccine’s use in older people&comma; despite limited data regarding its efficacy in people over 55&comma; citing the immune responses seen and experience with other vaccines&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;At least some protection is expected&comma;” Bruno Sepodes&comma; of the EMA’s expert committee&comma; said on Friday at a news briefing&period; He acknowledged that &OpenCurlyDoubleQuote;the exact level of protection cannot be estimated for the time being”&period;<&sol;p>&NewLine;<blockquote class&equals;"twitter-tweet" data-width&equals;"550" data-dnt&equals;"true">&NewLine;<p lang&equals;"en" dir&equals;"ltr">📢 EMA has just recommended granting a conditional marketing authorisation for the <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;COVID19vaccine&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;COVID19vaccine<&sol;a> AstraZeneca to prevent <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;COVID19&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;COVID19<&sol;a> in people from 18 years of age&period; 👉Read our press release&colon; <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;YDbOvZEMUN">https&colon;&sol;&sol;t&period;co&sol;YDbOvZEMUN<&sol;a> <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;Sbj6TdlGTW">pic&period;twitter&period;com&sol;Sbj6TdlGTW<&sol;a><&sol;p>&NewLine;<p>&mdash&semi; EU Medicines Agency &lpar;&commat;EMA&lowbar;News&rpar; <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;EMA&lowbar;News&sol;status&sol;1355171602531569664&quest;ref&lowbar;src&equals;twsrc&percnt;5Etfw">January 29&comma; 2021<&sol;a><&sol;p><&sol;blockquote>&NewLine;<p><script async src&equals;"https&colon;&sol;&sol;platform&period;twitter&period;com&sol;widgets&period;js" charset&equals;"utf-8"><&sol;script><&sol;p>&NewLine;<p>Many countries on the continent have been struggling to vaccinate people as quickly as Britain&comma; Israel&comma; the US and elsewhere&comma; and it was long hoped that the AstraZeneca shot would help speed things up at a time when countries face surging cases in a pandemic that has taken the lives of more than 400&comma;000 people in the 27-nation bloc&period;<&sol;p>&NewLine;<p>The EU bet heavily on the shot&comma; which is cheaper and easier to handle than some other vaccines&comma; with orders for 300 million doses to be delivered after authorisation and options for another 100 million doses&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;None of them is a magic wand on its own&comma; but together they provide tools and options to prevent different aspects of the disease&comma;” said Emer Cooke&comma; the head of the EMA&period;<&sol;p>&NewLine;<p>The AstraZeneca vaccine has been authorised for use in all adults in other countries&comma; even though only 12&percnt; of the participants in its research were over 55 and they were enrolled later&comma; so there has not been enough time to get results&period;<&sol;p>&NewLine;<p>EMA’s decision authorises AstraZeneca’s vaccine to be used across the bloc&comma; but individual countries can still decide how and to whom they will give the doses they receive&period;<&sol;p>&NewLine;<p>Lithuania&comma; for instance&comma; will not use the vaccine in older people&comma; the country’s deputy Health Minister Zivile Simonaityte said&comma; according to the Baltic News Service&period; It was not clear&comma; however&comma; what age groups would be given the shot&period;<&sol;p>&NewLine;<p>Germany has indicated it could follow a similar path&period;<&sol;p>&NewLine;<p>The country’s independent vaccine advisory committee recommended on Friday that the shot only be given to people under 65&period;<&sol;p>&NewLine;<p>The committee&comma; known by its German acronym STIKO&comma; said that &OpenCurlyDoubleQuote;there currently isn’t sufficient data to assess the vaccine effectiveness from the age of 65”&period;<&sol;p>&NewLine;<p>The final decision rests with the government&comma; but they are likely to follow this advice&period;<&sol;p>&NewLine;<p>Thomas Mertens&comma; the head of the German advisory committee&comma; said the general approval by EMA was &OpenCurlyDoubleQuote;confusing” in light of the data but that he and his colleagues would gladly update their recommendation if further data comes in&period; &OpenCurlyDoubleQuote;It’s not set in stone&comma;” he said&period;<&sol;p>&NewLine;<p>The EMA’s executive director declined to say whether the regulator saw a problem with such an approach&period;<&sol;p>&NewLine;<p>The agency assessed four trials in the UK&comma; Brazil and South Africa and said the research showed the vaccine proved to be about 60&percnt; effective by reducing the number of people who got sick&period;<&sol;p>&NewLine;<p>The trials have not yet shown whether the vaccine can stop disease transmission&period;<&sol;p>&NewLine;<p>A separate study testing the AstraZeneca vaccine in the US is still under way&period;<&sol;p>&NewLine;<p>Professor Andrew Pollard&comma; director of the Oxford Vaccine Group that developed the shot together with AstraZeneca&comma; welcomed the decision&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The recommendation by the European Medicines Agency is an important milestone in extending access to the Oxford&sol; AstraZeneca vaccine in our region and providing further endorsement that&comma; after the rigorous scrutiny of regulators&comma; the vaccine can be used to help protect populations from the coronavirus pandemic&comma;” he said in a statement&period;<&sol;p>&NewLine;<p>The EU has particularly lashed out at AstraZeneca after the drugmaker said it would supply less vaccine in a first batch than originally anticipated&period;<&sol;p>&NewLine;<p>Exacerbating concerns about supplies to the bloc&comma; which is home to some 450 million people&comma; Moderna told countries including Italy and Denmark the company would be delivering fewer vaccines than originally expected&period;<&sol;p>&NewLine;<p>Jens Spahn&comma; the German health minister&comma; said on Friday he understood many were waiting impatiently for the vaccine&comma; but cautioned that &OpenCurlyDoubleQuote;several hard weeks of vaccine shortage still lie before us”&period;<&sol;p>&NewLine;<p>Two more vaccine makers also recently announced results&comma; with Novavax saying this week that its shot appears 89&percnt; effective based on early findings and Johnson &amp&semi; Johnson saying its long-awaited single-shot vaccine was 66&percnt; effective at preventing moderate to severe illness&period;<&sol;p>&NewLine;<p>Also on Friday&comma; the European Commission introduced measures to tighten rules on the exports of shots produced in the 27 EU countries&period;<&sol;p>&NewLine;<p>The &OpenCurlyDoubleQuote;vaccine export transparency mechanism″ will be used until the end of March to control vaccine shipments to non-EU countries and to ensure that any exporting company based in the EU first submits its plans to national authorities&period;<&sol;p>&NewLine;<p>The EU insisted the measure is not an export ban&period;<&sol;p>&NewLine;<p>Officials said the mechanism would not affect humanitarian deliveries and shipments to countries covered by the COVAX initiative co-led by the World Health Organisation&period;<&sol;p>&NewLine;<p>The European Union and AstraZeneca also agreed on Friday to make public a heavily redacted version of their coronavirus vaccine agreement&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed3b3700d9a">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed3b3700d9a'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version